### International Corneal and Ocular Surface Disease Dataset for Electronic Health

2 Records

1

5

14

- 3 Darren S. J. Ting, 1,2,3,4,5 Stephen B. Kaye, Saaeha Rauz; for the International Corneal and
- 4 Ocular Surface Disease (C&OSD) Dataset Development Working Group\*
- <sup>\*</sup>Albert Jun, <sup>7</sup> Asim Ali, <sup>8,9</sup> Bernhard Steger, <sup>10</sup> Boris Malyugin, <sup>11</sup> Bruce Allan, <sup>12,13,14</sup> Charles
- 7 Bouchard, <sup>15</sup> Chie Sotozono, <sup>16</sup> Christopher S. Liu, <sup>17,18,19</sup> Darren S. J. Ting, <sup>1,2,3,4,5</sup> Deborah S.
- 8 Jacobs, <sup>20</sup> Francisco Arnalich-Montiel, <sup>21</sup> Geetha Iyer, <sup>5,22</sup> Gerd Geerling, <sup>23</sup> Hon Shing Ong, <sup>4,5,24</sup>
- 9 James Chodosh,<sup>20,25</sup> Jesper Hjortdal,<sup>26</sup> Michael K. O'Gallagher,<sup>27</sup> Mohammed Ziaei,<sup>28</sup> Mrinal
- 10 Rana.<sup>29</sup> Muhammad Moin.<sup>30</sup> Namrata Sharma.<sup>31</sup> Navpreet Dhillon.<sup>32</sup> Nicola Lau.<sup>12</sup> Oliver
- 11 Baylis, 33 Paolo Rama, 34 Reza Dana, 20 Rajesh Fogla, 35 Saaeha Rauz, 1,2 Sajjad Ahmad, 12,13,14
- 12 Shigeru Kinoshita, 36 Stephanie L. Watson, 37 Stephen B. Kaye, 6 Tom Butler, 38 Ula
- 13 Jurkunas. 39,40 Vito Romano 41
- 15 Department of Inflammation and Ageing, College of Medicine and Health, University of
- 16 Birmingham, Birmingham, UK.
- 17 <sup>2</sup> Birmingham & Midland Eye Centre, Sandwell and West Birmingham NHS Trust,
- 18 Birmingham, UK.
- <sup>3</sup> Academic Ophthalmology, School of Medicine, University of Nottingham, Nottingham, UK
- <sup>4</sup> Ophthalmology and Visual Sciences Academic Clinical Program (Eye-ACP), Duke-NUS
- 21 Medical School, Singapore.
- <sup>5</sup> Singapore Eye Research Institute, Singapore.
- <sup>6</sup> Department of Eye and Vision Science, Institute of Life Course and Medical Sciences,
- 24 University of Liverpool, Liverpool, UK.
- <sup>7</sup> Department of Ophthalmology, University of Virginia School of Medicine, Virginia, USA.
- <sup>8</sup> Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto,
- 27 Canada.

- <sup>9</sup> Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto,
- 29 Canada.
- 30 <sup>10</sup> Department of Ophthalmology, Medical University of Innsbruck, Christoph Probst Platz,
- 31 Austria.
- 32 <sup>11</sup> The Jules Stein Eye Institute, University of California at Los Angeles, David Geffen School
- 33 of Medicine, UCLA, Los Angeles, USA.
- 34 <sup>12</sup> Moorfields Eye Hospital, London, UK.
- 35 <sup>13</sup> University College London (UCL) Institute of Ophthalmology, London, UK.
- 36 <sup>14</sup> Moorfields/UCL NIHR Biomedical Research Centre, London, UK.
- 37 <sup>15</sup> Department of Ophthalmology, Stritch School of Medicine, Loyola University Chicago,
- 38 Maywood, USA.
- 39 <sup>16</sup> Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- 40 <sup>17</sup> Brighton and Sussex Medical School, Brighton & Hove, UK.
- 41 <sup>18</sup> Tongdean Eye Clinic, Brighton & Hove, UK.
- 42 <sup>19</sup> NHS Highland, Scotland, UK.
- 43 <sup>20</sup> Massachusetts Eve and Ear, Harvard Medical School, Boston, USA.
- 44 <sup>21</sup> Cornea Unit, Department of Ophthalmology, Ramón y Cajal University Hospital, Madrid,
- 45 Spain.
- 46 <sup>22</sup> CODE Eve Care, Chennai, India.
- 47 <sup>23</sup> Department of Ophthalmology, University Hospital Duesseldorf, Heinrich-Heine-University,
- 48 Germany.
- 49 <sup>24</sup> Corneal and External Diseases Department, Singapore National Eye Centre, Singapore.
- 50 <sup>25</sup> Department of Ophthalmology and Visual Sciences, University of New Mexico School of
- 51 Medicine, New Mexico, USA.
- 52 <sup>26</sup> Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
- 53 <sup>27</sup> Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
- 54 <sup>28</sup> Department of Ophthalmology, The University of Auckland, Auckland, New Zealand.

- 55 <sup>29</sup> Department of Ophthalmology, University Hospitals Coventry & Warwickshire NHS Trust,
- 56 Coventry, UK.
- 57 <sup>30</sup> King Edward Medical University, Mayo Hospital, Lahore, Pakistan.
- 58 <sup>31</sup> Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical
- 59 Sciences, New Delhi, India.
- 60 <sup>32</sup> Department of Ophthalmology, University Hospitals of Leicester, Leicester, UK.
- 61 <sup>33</sup> Sunderland Eye Infirmary, Sunderland, UK.
- 62 <sup>34</sup> Ophthalmology Unit I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.
- 63 <sup>35</sup> Department of Ophthalmology, Apollo Hospitals, Jubilee Hills, Hyderabad, India.
- 64 <sup>36</sup> Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto
- 65 Prefectural University of Medicine.
- 66 37 Save Sight Institute, Sydney Eye Hospital, Faculty of Medicine and Health, Sydney,
- 67 Australia.

80

- 68 <sup>38</sup> Paget University Hospital, Great Yarmouth, Norfolk, UK.
- 69 Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, USA.
- 70 <sup>40</sup> Department of Ophthalmology, Harvard Medical School, Boston, USA.
- 71 Eye Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and
- 72 Public Health, University of Brescia, Brescia, Italy.
- 74 **Corresponding author:** Professor Saaeha Rauz
- 75 Address: Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre,
- 76 Department of Inflammation and Ageing, College of Medicine and Health, University of
- 77 Birmingham, Dudley Road, Birmingham B18 7QU, United Kingdom.
- 78 **Email:** s.rauz@bham.ac.uk
- 79 **Tel:** +44 (0)121 554 3801 Ext. 6996
- Funding/support: DSJT acknowledges the support from Birmingham Health Partners (BHP)
- 82 Clinician Scientist Fellowship. SR is funded by the National Institute for Health and Care

Research (NIHR) under its Invention for Innovation (i4i) (II-LA-1117-20001); UKRI Medical Research Council Experimental Medicine Award (MR/X019195/1). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care or MRC. JC acknowledges funding from the NIH grants (EY021558 and EY013124). Conflict of interest: AA receives consultant fees and grant support from Santen, Inc., Japan. All other authors have no conflict of interest to declare. **ORCID** details: Darren S. J. Ting: https://orcid.org/0000-0003-1081-1141 Stephen Kaye: https://orcid.org/0000-0003-0390-0592 Saaeha Rauz: https://orcid.org/0000-0003-4627-3496 Hon Shing Ong; https://orcid.org/0000-0001-5475-8712 Mohammed Ziaei; https://orcid.org/0000-0002-1289-3796 Vito Romano; https://orcid.org/0000-0002-5148-7643 Key words: Big data; Cornea; Dataset; Electronic health record; Electronic patient record

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

**ABSTRACT** Background/Aims: To provide a comprehensive and internationally standardised Cornea and Ocular Surface Disease (C&OSD) dataset for use in electronic health records (EHRs). Methods: This was an international consensus study conducted through roundtable discussions involving 35 international experts specialising in the field of C&OSD. The Royal College of Ophthalmologists dataset guidelines were used to articulate initial C&OSD data elements template by curating data elements from validated published datasets obtained through scientific literature searches, and accessing existing international patient clinical and reported outcome recording instruments and registries. These included data elements recommended by the Dry Eye Workshop II, International Meibomian Gland Dysfunction Workshop, Ocular Surface Disease Activity and Damage Indices, the Cicatrising Conjunctivitis Assessment Tool, Limbal Stem Cell Deficiency Clinical and Confocal Grading, Chronic Ocular Manifestations in Patients with Stevens-Johnson Syndrome, and the UK Transplant Registry. Data elements pooled into an independent operational data model. Results: A comprehensive generic dataset (common to all ophthalmology datasets) and C&OSD specific dataset was developed. Within the C&OSD dataset, several gateway disease datasets, such as atopic or allergic eye diseases, meibomian gland dysfunction, cicatrising conjunctivitis, chemical injury, dry eye, limbal stem cell deficiency, microbial or infectious keratitis, corneal erosion syndrome, and keratoconus, were established to streamline data entry for clinical audit and research purposes. Conclusion: A comprehensive C&OSD dataset is provided which can be used by both generalist and specialist ophthalmologists. Adoption of the full dataset by EHR providers will lead to better interoperability and patient care and facilitate international research collaboration.

### INTRODUCTION

The advent of electronic patient or health records (EHR) has significantly transformed the landscape of healthcare systems. Since the inception of EHR in 1970s and subsequent development in 1990s, EHR systems have increasingly been adopted over the past decade across all branches of medicine, including ophthalmology, to replace traditional paper-based patient records. As of November 2023, 90% of the National Health Service (NHS) trusts in the UK have embraced EHR systems within their healthcare services as part of the digital transformation strategy of NHS Long Term Plan. As of NHS Long Term Plan.

EHR offers a multitude of advantages over traditional paper-based patient records.<sup>5</sup> In 2016, the Global Observatory for eHealth (by the World Health Organisation) published the third global survey on eHealth,<sup>6</sup> that highlighted the benefits of EHR systems in improving the quality, accuracy, reliability, and timeliness of patient information at the point of care. EHR systems can also provide linkages to other hospital information systems such as laboratory, pathology, imaging, and pharmacy information systems, and allow effective and efficient sharing of clinical information among different healthcare providers. Such shared-care records are an essential component underlying interoperability. In addition, EHRs enable the seamless capture of millions of clinical data points, which in turn can facilitate big data and artificial intelligence research.<sup>7,8</sup> The availability of these real-world "big data" allows for a comprehensive and timely examination of the epidemiology, clinical characteristics, management, outcomes, and prognostic factors of diseases. Making better use of data and digital technology is a key component of the NHS Long Term Plan.<sup>4</sup>

Several barriers affecting implementation of EHR systems in healthcare have been reported in the real-world settings.<sup>6,9,10</sup> These include the lack of funding, capacity, and infrastructure, legal issues related to data privacy and security, and time spent on the EHR systems by the clinicians (which may reduce patient-clinician interaction time). Moreover, many of the EHR systems are introduced for largely clinical and administrative purposes with secondary

extraction for outcome monitoring, audit and research usage. Such EHR systems are designed to support generic medical data collection, with few specifically designed for medical or surgical specialties and subspecialties.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

Ophthalmology-specific EHR systems such as Medisoft/Medisight (Medisoft Ltd, Leeds, UK) and OpenEyes (Apperta Foundation, Sunderland, UK) have been implemented into several centres. The content and standardisation of these do not sufficiently meet ophthalmic subspeciality requirements and the lack of integration of these ophthalmology-specific EHR with generic medical EHR systems (e.g. Epic, Oracle, etc.) compromises patient care in the setting of multisystemic disease and conceals eye healthcare management strategies from other specialists. This not only hinders seamless access and exchange of ophthalmic and non-ophthalmic information between the electronic systems but may also pose major clinical risks due to incomplete patient information and assessment. The main functional components of an EHR are a clinical data repository, decision support system, order entry system, patient portal, and reporting system. Within the generic system, there should be a dedicated ophthalmic module/system (for each ophthalmology sub-speciality) to unify data capture across all EHR systems in order to standardise cross-institutional data collection and auditing. Moreover, not all ophthalmology units have adopted eye-dedicated EHRs, and clinical documentation is frequently restricted to free text entry or 'form filling' in generic EHR platforms.

In the UK, the ophthalmic EHR systems have supported secondary data analyses through the Royal College of Ophthalmologists (RCOphth) National Ophthalmology Databases (NOD). These currently focus on audit and research areas related to cataract surgery and age-related macular degeneration. There are no current NODs for corneal and ocular surface disease.

Datasets for the NOD provide specification for data collections and for data analyses for the benefit of improving standards of eye healthcare. They refer to a set of defined variables

representing clinical information about a patient with a given condition and the format they should take. The RCOphth is committed to standardisation of data content (variables with grading scales), data type and format that meets Core Information Standards (CIS), ready for electronic use i.e., regardless of locality and which EHR system is being used, the curated data should be identical enabling subsequent pooling and comparisons of data to facilitate outcome monitoring and delivery of excellence in patient care.<sup>14</sup>

The purpose of this study is to: (i) establish an internationally agreed complete data itemisation proposed standard required to care for a patient with corneal and ocular surface disease (C&OSD), (ii) identify a library of data archetypes of commonly used items (such as visual acuity or intraocular pressure) that could be harmonised across all ophthalmological sub-specialty datasets, and (iii) embed functionality to extract sub-datasets to perform audit or report clinical outcomes such as following comeal transplant or after administration of high cost commissioned drugs or hospitalisation. Ultimately, we will seek designation of an Information Standards Notice (ISN) to demonstrate the minimum regulatory standard for reporting C&OSD in EHR systems.

# **MATERIALS AND METHODS**

The development and standardisation of international core dataset for C&OSD, the "Minimum Viable Information Standard (MVIS)", followed the Professional Record Standards Body (PRSB) core information standards guidance that defines "best practice-based evidence with widescale consultation and input from users and relevant stakeholders". Ethical approval was not required for establishing a C&OSD dataset proposed standard. All aspects of the workflow were conducted in accordance with the tenets of declaration of Helsinki.

# **C&OSD** proposed dataset standard workflow

The C&OSD EHR standard development group (EHR-SDG) consisted of 12 self-selected consultant ophthalmologists [SR (Lead), SBK (co-Lead), BA, CSL, DSJT, MKO'G, MR, ND, NL, OB, SA, and TB] from the Bowman Club (the UK corneal consultants consortium) and an international leaders working group of corneal and ocular surface disease experts by invitation AA, AJ, BS, BM, CB, CS, DSJ, FA, GI, GG, HSO, JC, JH, MM, MZ, NS, PR, RF, RD, SK, SLW, UJ, VR). Four rounds of online roundtable discussion, each lasting around 1-2 hours, were held amongst the UK expert panel between 27/09/2022 and 24/06/2023, with international consultation and validation held between 29/01/2023 and 15/03/2023. This was followed by one further (and final) meeting among UK experts on 20/03/2023 to discuss any remaining issues and finalise the international datasets prior to ratification by the RCOphth Quality and Standards Committee (version 1.0 published 16/07/2023). In the UK, a submission to the PRSB for a designated ISN is planned and it is intended that for all other countries a similar approach to the relevant patient record regulatory body will be undertaken. The conduct of this international consensus study is summarised in **Figure 1**.

## Construction and ordering of data elements

The RCOphth dataset guidelines from the Informatics Committee<sup>14</sup> were used to articulate the initial C&OSD data elements template by curating data elements from validated published datasets for relevant conditions. The data elements were obtained through scientific literature search, or by access to existing international and national patient clinical and reported outcome recording instruments and registries. Validated datasets with health outcomes measurements or those agreed through large international consensus groups or the international consortium of health outcomes measurement (ICHOM) were included. Data elements for the assessment of corneal and ocular surface disease recommended by the Dry Eye Workshop II, International Meibomian Gland Dysfunction Workshop, Ocular Surface Disease Activity and Damage Indices, the cicatrising conjunctivitis assessment tool, Limbal Stem Cell Deficiency Clinical and Confocal Grading. Chronic Ocular Manifestations in Patients with Stevens—Johnson Syndrome, Unical and Confocal

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

Transplant Registry – Ocular Tissue Outcome and Transplant Record<sup>22</sup> (to substitute local transplant registry dataset), and RCOphth Cross-Linking Data Set<sup>23</sup> (to substitute local CXL dataset) were extracted. Patient-reported outcome measures such as OSDI, IDEEL, and SANDE, were also included. Data elements were pooled into an independent operational data model created with Microsoft Excel hosted on Sharepoint server. Duplicates were removed and a library of commonly used items (such as visual acuity or intraocular pressure) that could be harmonised across all ophthalmological sub-specialty datasets were identified and labelled as 'generic'. Those specific to C&OSD were ordered into a coherent format using an explicit, empirically based approach to defining and naming relevant clinical constructs and assigning category and data type. 14 Category assignment comprised of three categories: 'Mandatory' (data items which are essential for all applications, and must be collected), 'Desirable' (advised as valuable for audit or knowledge extraction purposes) and 'Optional' (data items which are required for some applications, and may be collected) Data type assignment used structured query language (SQL) for managing and manipulating data in relational databases summarised below: TYPE: Description NULL: A special entity representing an uncertain or unassigned value INTEGER: An integer value, normally unsigned (i.e. zero or positive values only) FLOAT: A floating-point value, positive or negative (avoid spurious precision) BOOL: A value representing true or false STRING: A value containing text (alphanumeric data) of unspecified length ENUM: A value which represents one of a limited range of values

277 DATE: A value representing a date 278 DATETIME: A value representing a date and time 279 LIST: An entity containing one or more values 280 Drawing templates were also adapted from the existing datasets or created new. 281 **RESULTS** 282 283 A total of 35 international experts (from 15 countries) in the field of C&OSD were included in 284 this study (Supplementary Table 1). Prior to each meeting, the dataset was distributed for 285 comment and to identify missing, redundant or duplicated data fields, conditions or diseases 286 that were not captured by the data fields, terminology (in particular if country specific), 287 alignment with consensus standards for reporting and analysis of data (e.g., refractive and 288 keratometric data) together with a navigational information video (Supplementary Video 1). 289 The data fields were then amended with various elements being introduced at different 290 stages and were further discussed at each meeting as an iterative process. 291 A full dataset was developed after five rounds of roundtable meetings (Figure 2). This 292 293 dataset was then divided into generic dataset (which is common to all ophthalmology 294 datasets) and C&OSD specific dataset. The generic datasets included four main domains, 295 encompassing demographics, previously known general/ophthalmic diagnoses, general 296 medical examination, and general ophthalmic examination. C&OSD included existing UK 297 national datasets for corneal cross-linking, corneal transplant, and serum eye drops, as well 298 as gateway diseases, which were brought in during the first national consultation. Nine 299 gateway diseases (and their associated specific datasets) were created to facilitate specific 300 data collection. These included blepharitis, dry eye disease, conjunctivitis (including simple, 301 allergic/atopic, and cicatrising conjunctivitis), microbial/infectious/HSV keratitis, keratoconus, 302 recurrent corneal erosion syndrome, chemical eye injury, and limbal stem cell deficiency 303 (Figure 2). In order to account for colloquial preferences and to be inclusive for similar terms

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

used for common conditions, subheadings included such additional colloquial terms. For example, corneal 'ulcer' was separated into (i) corneal abscess/infiltrate and (ii) corneal ulcer. Several drawing templates were created for facilitating the documentation of various C&OSD. Full details of the C&OSD datasets are accessible in the supplement and via the following link to The RCOphth Clinical Data Sets webpage (https://www.rcophth.ac.uk/standards-andquidance/audit-and-data/clinical-data-sets/) where the dataset will be maintained and updated on a minimum of a biennial basis. DISCUSSION Standardisation is the process of creating, issuing and implementing standards. A standard is a document, established by consensus and approved by a recognised body. It provides rules, guidelines or characteristics for activities or their results so that they can be repeated.<sup>24</sup> The establishment of a minimum clinical dataset serves as a critical component of the healthcare system where it helps ensure the delivery of high quality care to individual patients as well as enable standardised clinical data collection, audit and research.<sup>25</sup> This work represents the first international clinician-driven, standardised dataset for C&OSD. The proposed dataset is suitable for both general ophthalmologists and those with special interest in C&OSD. In addition, the involvement of experts from around the world ensured the comprehensiveness and generalisability of the dataset to be adopted in any country. The development of this seminal C&OSD dataset may not only help standardise the documentation of various C&OSD globally, but also enable interoperability and better patient care as well as facilitate collaborative multi-centre big data research on these conditions in the future. To date, a few ophthalmic EHR systems have been developed and implemented across the world. One of the most significant examples is the Intelligent Research in Sight (IRIS)

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

Registry, a US-based ophthalmic EHR registry established by the American Academy of Ophthalmology in 2014.<sup>26,27</sup> As of October 2021, the IRIS Registry had captured data from >70 million patients (with >400 million patient visits) contributed by around 16,000 eye clinicians, serving as a powerful resource for benchmarking clinical performance and patient care/outcomes, epidemiological studies, scientific discovery, and big data research.<sup>27</sup> In addition, the availability of high-quality big data provide invaluable opportunities for artificial intelligence (AI) research. 7,28 So far, the IRIS Registry has enabled research in nearly all branches of ophthalmology, including corneal and ocular surface diseases.<sup>29-33</sup> For instance, by analysing the data from >5 million patients in IRIS registry, Singh et al. 33 were able to determine the case frequency of corneal opacity (6.5% of all patients) and identify the underlying causes and prognostic factors for poor visual outcomes, providing important insights into the epidemiology and unmet clinical/research needs of this important condition. Similarly, Das and Basu<sup>34</sup> were able to identify >20,000 patients presented with epidemic keratoconjunctivitis and characterised the clinical features and outcomes using data of >2 million patients derived from EHR, improving the understanding of this prevalent disease. The Save Sight Dry Eye Registry, operational since 2020, has collected global real-world outcomes on the most common ocular surface disease (i.e. dry eye disease) and the Save Sight Keratoconus Registry on the outcomes of keratoconus since 2015. 35,36 These registries have discovered that the impacts on quality of life of keratoconus are greater than macular disease, reported on disease natural history, crosslinking outcomes and treatment patterns in dry eye disease. 35,37-39 The registries have also enabled clinicians to benchmark their practice and obtain credit towards continuing professional development accreditation.

Bearing in mind the demanding volume of C&OSD patients presenting to clinics and hospitals and the amount of time required for documentation using EHR systems, 10,40 a number of gateway diseases were created to improve the clinical documentation of several prevalent and important C&OSD. In particular, we included common C&OSD conditions such as blepharitis, dry eye disease, conjunctivitis (including simple and allergic/atopic

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

conjunctivitis), infectious (microbial and HSV) keratitis, keratoconus, recurrent corneal erosion syndrome, and chemical eye injury, as well as more specialised or rare conditions like cicatrising conjunctivitis and limbal stem cell deficiency. Other gateway diseases can be customised peculiar to the centre and clinical needs, e.g. Fuchs' endothelial dystrophy, ocular surface neoplasia, and others. The Save Sight Keratoconus and Dry Eye Registries data fields are based on parsimony to ensure capability of data collection with everyday clinical practice.<sup>41</sup> Overtime review of data entry using the C&OSD dataset based on parsimony may enable more efficient data entry.

One of the main intentions for the creation of the C&OSD dataset is to provide a dataset that is comprehensive and that can only work if it is adopted in full. Many of the EHRs that have been developed and supplied off the shelf have been selective in the data fields and/or have amended and modified the fields and terminology. This means that the components of many conditions are not adequately captured, and the lack of consistency severely limits interoperability and patient care. Provision of a common C&OSD dataset that is supported by international experts provides the EHR providers with a unique opportunity to improve patient care and facilitate knowledge exchange. While it is hoped that this C&OSD dataset is voluntarily adopted by EHR providers, it is also intended that the dataset becomes mandated. Each country will have their own mechanisms for this. In the UK, it will be achieved via an ISN. Alignment with Continuing Professional Development accreditation or outcome reporting for high cost or novel medical intervention requirements in other countries may facilitate uptake. The dataset that is provided, however, is not meant to be static and will need to be updated to keep abreast with advances in field and to include improvements with a set minimum biennial review cycle Similarly, it is essential that the views of new experts are included. In the future, the integration of AI and clinical registries may facilitate big data research using the C&OSD dataset. 7,28 In order, to ensure the data remains up to data and utilises available technology, the dataset will be reviewed every 2 years under the

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

governance of the RCOphth who will maintain the dataset and to whom comments and corrections can be submitted. In conclusion, we have developed a comprehensive C&OSD dataset for both the generalists and specialists, through an international taskforce. We envisage that the adoption of the full dataset by EHR providers will lead to better interoperability and patient care and facilitate wider international research collaboration in the future. References DesRoches CM, Campbell EG, Rao SR, Donelan K, Ferris TG, Jha A, et al. Electronic health records in ambulatory care--a national survey of physicians. N Engl J Med. 2008;359(1):50-60. Jha AK, DesRoches CM, Campbell EG, Donelan K, Rao SR, Ferris TG, et al. Use of electronic health records in U.S. hospitals. N Engl J Med. 2009;360(16):1628-38. 3. https://digital.nhs.uk/news/2023/90-of-nhs-trusts-now-have-electronic-patient-records. https://www.longtermplan.nhs.uk/. Sauer CM, Chen LC, Hyland SL, Girbes A, Elbers P, Celi LA. Leveraging electronic health records for data science: common pitfalls and how to avoid them. Lancet Digit Health. 2022;4(12):e893-e8. World Health Organization. Global Diffusion of eHealth: Making universal health coveraage achievable. In: eHealth. GOfeRotTGSo, editor. Geneva, Switzerland2016. Ting DSJ, Deshmukh R, Ting DSW, Ang M. Big data in corneal diseases and cataract: Current applications and future directions. Front Big Data. 2023;6:1017420. Khennou F, Khamlichi YI, Chaoui NEH. Improving the Use of Big Data Analytics within Electronic Health Records: A Case Study based OpenEHR. Procedia Computer Science. 2018;127:60-8.


- 415 9. Detmer DE, Gettinger A. Essential Electronic Health Record Reforms for This Decade.
- 416 Jama. 2023;329(21):1825-6.
- 417 10. Rotenstein LS, Holmgren AJ, Horn DM, Lipsitz S, Phillips R, Gitomer R, et al. System-
- 418 Level Factors and Time Spent on Electronic Health Records by Primary Care
- 419 Physicians. JAMA Netw Open. 2023;6(11):e2344713.
- 420 11. https://nodaudit.org.uk/.
- 421 12. Ting DSJ, Tatham AJ, Donachie PHJ, Buchan JC. The Royal College of
- 422 Ophthalmologists' National Ophthalmology Database study of cataract surgery: report
- 423 16, influence of remuneration model on choice of intraocular lens in the UK. Eye (Lond).
- 424 2023;37(18):3854-60.
- 425 13. Buchan JC, Norridge CFE, Barnes B, Olaitan M, Donachie PHJ. The Royal College of
- 426 Ophthalmologists' National ophthalmology database study of cataract surgery: Report
- 427 14, cohort analysis the impact of CapsuleGuard® utilisation on cataract surgery
- posterior capsule rupture rates. Eye (Lond). 2024;38(9):1702-6.
- 429 14. https://www.rcophth.ac.uk/wp-content/uploads/2021/10/Dataset-Guidelines.pdf.
- 430 15. https://theprsb.org/core-information-standard-v2-0/.
- 431 16. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS
- DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15(3):539-74.
- 433 17. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international
- workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest
- 435 Ophthalmol Vis Sci. 2011;52(4):2006-49.
- 436 18. Mathewson PA, Williams GP, Watson SL, Hodson J, Bron AJ, Rauz S. Defining Ocular
- 437 Surface Disease Activity and Damage Indices by an International Delphi Consultation.
- 438 Ocul Surf. 2017;15(1):97-111.
- 439 19. Ong HS, Minassian D, Rauz S, Mehta JS, Dart JK. Validation of a clinical assessment
- tool for cicatrising conjunctivitis. Ocul Surf. 2020;18(1):121-9.

- 20. Aravena C, Bozkurt K, Chuephanich P, Supiyaphun C, Yu F, Deng SX. Classification of
- Limbal Stem Cell Deficiency Using Clinical and Confocal Grading. Cornea.
- 443 2019;38(1):1-7.
- 21. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading
- 445 system for the evaluation of chronic ocular manifestations in patients with Stevens-
- 446 Johnson syndrome. Ophthalmology. 2007;114(7):1294-302.
- 447 22. https://www.odt.nhs.uk/statistics-and-reports/access-data/.
- 448 23. https://www.rcophth.ac.uk/wp-content/uploads/2020/09/Corneal-Cross-Linking-Data-
- 449 Set-July-2016.pd.
- 450 24. https://www.gov.uk/guidance/standardisation.
- 451 25. Svensson-Ranallo PA, Adam TJ, Sainfort F. A framework and standardized
- 452 methodology for developing minimum clinical datasets. AMIA Jt Summits Transl Sci
- 453 Proc. 2011;2011:54-8.
- 454 26. Chiang MF, Sommer A, Rich WL, Lum F, Parke DW, 2nd. The 2016 American Academy
- of Ophthalmology IRIS(®) Registry (Intelligent Research in Sight) Database:
- 456 Characteristics and Methods. Ophthalmology. 2018;125(8):1143-8.
- 457 27. Lee CS, Blazes M, Lorch A, Pershing S, Hyman L, Ho AC, et al. American Academy of
- 458 Ophthalmology Intelligent Research in Sight (IRIS®) Registry and the IRIS Registry
- 459 Analytic Center Consortium. Ophthalmol Sci. 2022;2(1):100112.
- 460 28. Tran L, Kandel H, Sari D, Chiu CH, Watson SL. Artificial Intelligence and Ophthalmic
- 461 Clinical Registries. Am J Ophthalmol. 2024;268:263-74.
- 462 29. Anchouche S, Hall N, Bal S, Dana R, Elze T, Miller JW, et al. Chemical and thermal
- ocular burns in the United States: An IRIS registry analysis. Ocul Surf. 2021;21:345-7.
- 464 30. Son HS, Lum F, Li C, Schein O, Pramanik S, Srikumaran D. Risk Factors for Repeat
- 465 Keratoplasty After Endothelial Keratoplasty-An IRIS Registry Analysis. Am J Ophthalmol.
- 466 2022;242:77-87.

- 467 31. Oke I, Elze T, Miller JW, Lorch AC, Hunter DG, Traish AS. The prevalence and
- 468 recurrence risk of bare sclera pterygium surgery in the United States. Ocul Surf.
- 469 2023;29:547-9.
- 470 32. Syed ZA, Tomaiuolo M, Zhang Q, Prajna V, Hyman L, Rapuano CJ. Trends and
- Sociodemographic Patterns in Keratoconus Management 2015-2020: An American
- 472 Academy of Ophthalmology IRIS® Registry Analysis. Ophthalmology. 2024;131(8):892-
- 473 901.
- 474 33. Singh RB, Dohlman TH, Ivanov A, Hall N, Ross C, Elze T, et al. Corneal Opacity in the
- 475 United States: An American Academy of Ophthalmology IRIS® Registry (Intelligent
- 476 Research in Sight) Study. Ophthalmology. 2024; doi: 10.1016/j.ophtha.2024.07.005.
- 477 34. Das AV, Basu S. Epidemic keratoconjunctivitis in India: electronic medical records-
- driven big data analytics report IV. Br J Ophthalmol. 2022;106(3):331-5.
- 479 35. Watson S, Chidi-Egboka N, Khoo P, Cabrera-Aguas M, Stapleton F, Geerling G, et al.
- 480 Efficient capture of dry eye data from the real world: The Save Sight Dry Eye Registry.
- 481 AJO International. 2024;1(3):100065.
- 482 36. Ferdi A, Nguyen V, Kandel H, Tan JCK, Arnalich-Montiel F, Abbondanza M, et al.
- 483 Predictors of progression in untreated keratoconus: a Save Sight Keratoconus Registry
- 484 study. Br J Ophthalmol. 2022;106(9):1206-11.
- 485 37. Kandel H, Nguyen V, Piermarocchi S, Ceklic L, Teo K, Arnalich-Montiel F, et al. Quality
- 486 of life impact of eye diseases: a Save Sight Registries study. Clin Exp Ophthalmol.
- 487 2022;50(4):386-97.
- 488 38. Kandel H, Abbondanza M, Gupta A, Mills R, Watson AS, Petsoglou C, et al.
- 489 Comparison of standard versus accelerated corneal collagen cross-linking for
- 490 keratoconus: 5-year outcomes from the Save Sight Keratoconus Registry. Eye (Lond).
- 491 2024;38(1):95-102.
- 492 39. Kandel H, Chen J, Sahebjada S, Chong E, Wiffen S, Watson S. Cross-linking improves
- 493 the quality of life of people with keratoconus: A cross-sectional and longitudinal study
- From the Save Sight Keratoconus Registry. Cornea. 2023;42(11):1377-83.

40. Nair D, Brereton L, Hoge C, Plantinga LC, Agrawal V, Soman SS, et al. Burnout Among Nephrologists in the United States: A Survey Study. Kidney Med. 2022;4(3):100407. 41. Gliklich RE, Dreyer NA, Leavy MB. Registries for Evaluating Patient Outcomes: A User's Guide. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014. FIGURE LEGENDS Figure 1. The timeline of the process of developing the international Corneal and Ocular Surface Disease (C&OSD) dataset. \*These include Dry Eye Workshop II, International Meibomian Gland Dysfunction Workshop, Ocular Surface Disease Activity and Damage Indices, the cicatrising conjunctivitis assessment tool, Limbal Stem Cell Deficiency Clinical and Confocal Grading, Chronic Ocular Manifestations in Patients with Stevens-Johnson Syndrome, UK Transplant Registry -Ocular Tissue Outcome and Transplant Record, and RCOphth Cross-Linking Data Set. PRSB = Professional Record Standards Body; ISN = Information Standards Notice **Figure 2.** Organisational components of the full dataset, including examples of common putative gateway diseases and Corneal and Ocular Surface Disease (C&OSD) dataset.

# TIMELINE FOR DEVELOPMENT OF INTERNATIONAL C&OSD DATASET



Submission of the dataset to PRSB for a designated ISN is planned. Dataset will also be reviewed biennially to ensure the dataset remains contemparory.

# Organisational Components

